Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

BOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%.

For comparison, published studies using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of 8 to 11 months and one-year survival rates of 33% to 43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months for patients treated with chemotherapy alone. Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15% at two years, respectively.

"The two-year survival rate of 30% in our Phase 1/2 NSCLC study compares favorably to the survival reported for Avastin plus paclitaxel and carboplatin chemotherapy," said Scott Cormack, president and CEO of OncoGenex. "These data remain consistent with our Phase 2 data in prostate cancer suggesting that OGX-011 when added to chemotherapy may improve survival by blocking the production of clusterin, the protein associated with treatment resistance in various cancers."

    Non-Small Cell Lung Cancer Phase 1/2 Study Design with Updated Results as
    of January 23, 2009

This single-arm, open-label study enrolled 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC who were treated with OGX-011 in combination w
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide ... kill nematodes. Nematodes are microscopic parasitic roundworms, found ... and inside other plants and animals. Nematicides have ... or other properties promoting migration through the soil. ... than 1,000 plant-parasitic nematodes. With more than 10,000 ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of Electro ... up large quantities of water, announced today that in ... the launch of the company's CLEAN-FRACâ„¢ industrial grade demonstrator ... STW Resources . , Immediately upon startup, the ... and achieved a 99.8% reduction in Turbidity on flowback ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... databases enable researchers to quickly and effectively use these invaluable resources. ... ... OpenHelix today announced the availability of an updated suite ... Textpresso. Gene Ontology is a consortium project developed to ...
... 5, Rosetta Genomics Ltd (Nasdaq: ROSG ), a ... today,that it will present at RBC Capital Markets 2008 ... at the Westin Hotel in New York. , ... of the presentation will be available on the,"Investors" section ...
... CITY, Calif., Dec. 5 Genomic Health,Inc. (Nasdaq: ... present results from,four studies at the 31st Annual San ... the Henry B. Gonzalez Convention Center. Two,of the ... physicians currently use to predict the likelihood of chemotherapy,benefit ...
Cached Biology Technology:New and Updated Online Tutorials for Textpresso and Gene Ontology 2Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 2Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 3Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium 2Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium 3
(Date:9/30/2014)... Ocean Health Index rates the Earth,s oceans at ... addition, for the first time, the report assessed ... national jurisdiction (high-seas areas) all critical regions ... providing sustainable food sources. , In the third ... by scientists from UC Santa Barbara,s National Center ...
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Salk scientists receive $3 million for BRAIN Initiative grant 2Shape up quickly -- applies to fish, too! 2
... German . Moscow/Stuttgart/ Halle(Saale). Parts of the ... have been rising steeply since 1990 also there. This is ... 400 years produced on the base of tree rings from ... tree growth using ring width of pine from Russia,s Kola ...
... self-assembly of molecular threads into the proteins that make ... thought, Michigan State University scientists say. That discovery could ... some diseases. How proteins spontaneously "fold" from wiggling ... functional or malfunctioning three-dimensional molecules is one ...
... Today, the Association for Molecular Pathology (AMP) submitted written comments ... National Institutes of Health (NIH) for its Genetic Test Registry ... formulate a comprehensive response to the RFI. "With the ... AMP is able to inform the NIH on the general ...
Cached Biology News:Signs of reversal of Arctic cooling in some areas 2Signs of reversal of Arctic cooling in some areas 3Signs of reversal of Arctic cooling in some areas 4Scientists post lower speed limit for cell-signaling protein assembly 2AMP responds to Genetic Test Registry request for information 2
Guanine nucleotide-binding protein G(k), alpha subunit...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
... P7 D7 F5] to RYK ( ... Antigen: Synthetic ... to amino acids 462 - 475 ... Gene ID: 6259 ...
DAP12 Market Segment: Protein Kinases...
Biology Products: